Despite the reduced incidence of coronary heart disease with intensive risk factor management, people with diabetes mellitus and prediabetes remain at increased coronary heart disease risk. Diabetes prevention interventions may be needed to reduce coronary heart disease risk. This approach was examined in the DPP (Diabetes Prevention Program) and the DPPOS (Diabetes Prevention Program Outcome Study), a long-term intervention study in 3234 subjects with prediabetes (mean±SD age, 64±10 years) that showed reduced diabetes risk with lifestyle and metformin compared with placebo over 3.2 years.
T he incidence of coronary heart disease (CHD) is increased ≈2-fold in type 2 diabetes mellitus, and CHD remains the single most important cause of morbidity and mortality in diabetes mellitus. 1 Interventions targeting factors that accelerate coronary atherosclerosis such as dyslipidemia, hypertension, hyperglycemia, and a procoagulant state have contributed to the significantly reduced incidence of CHD in the general population in recent years. 2 However, despite intensive management of CHD risk factors and parallel reductions in overall rates of CHD in diabetes mellitus, there remains considerable diabetes-related excess CHD risk, suggesting that there are limitations to the benefits of these CHD-targeted clinical interventions in established diabetes mellitus. 3 Greater success in reducing CHD may thus be achieved by initiating preventive approaches as early as possible in the course of diabetes mellitus, including diabetes prevention itself. For example, lifestyle or pharmacological interventions for diabetes prevention, implemented early in the progression from prediabetes to diabetes mellitus when clinical CHD events are less common, may be the key to fundamentally altering the increased risk of atherosclerosis in this disease.
The DPP (Diabetes Prevention Program) and DPPOS (Diabetes Prevention Program Outcome Study) make up one of the few clinical trials testing the effects of therapeutic interventions in subjects with prediabetes on long-term health outcomes. DPP demonstrated that intensive lifestyle change or metformin treatment reduced the incidence of diabetes mellitus and improved the cardiovascular disease (CVD) risk profile in a cohort of subjects at high risk for diabetes mellitus. 4 Because the onset of diabetes mellitus was systematically ascertained through semiannual assessments, it was possible to demonstrate that development of diabetes mellitus was accompanied by deterioration of cardiovascular risk factors in DPP and DPPOS. 5, 6 However, to date, there are too few CVD events to assess the effect of our interventions on these outcomes. Coronary artery calcium (CAC) measurements reflect total coronary atherosclerotic burden and provide an effective, noninvasive tool to predict CHD events in cohorts with and without type 2 diabetes mellitus and without known CHD. 7, 8 We performed measurements of CAC to assess DPP/DPPOS treatment effects on this early marker of subclinical coronary atherosclerosis.
METHODS
Written informed consent was obtained from all participants, and the studies were approved by the institutional review board at each clinical center ( Figure 1 shows the CONSORT [Consolidated Standards of Reporting Trials] flow diagram).
DPP Design
The DPP was a randomized clinical trial comparing metformin treatment or an individual behavioral lifestyle intervention program with placebo in preventing or delaying incident diabetes mellitus. 4 Inclusion criteria were age ≥25 years, body mass index (BMI) ≥24 kg/m 2 (≥22 kg/m 2 in Asian Americans), fasting plasma glucose levels between 95 and 125 mg/ dL, and impaired glucose tolerance (2-hour postload glucose of 140-199 mg/dL). Those taking medications known to alter glucose tolerance, had experienced a CVD event in the prior 6 months, or had illnesses that reduced their ability to participate were excluded. Participants were randomly assigned to 1 of 3 interventions: metformin 850 mg twice daily, placebo twice daily, or an intensive program of lifestyle modification. Treatment assignments were stratified according to clinical center and double-blinded for the metformin and placebo groups. The goals of lifestyle change were to achieve and maintain a weight reduction of at least 7% of initial body weight through consumption of a low-calorie, low-fat diet and to engage in moderate physical activity for at least 150 min/wk. Diabetes mellitus was diagnosed on the basis of an annual oral glucose tolerance test or a semiannual fasting plasma glucose test according to American Diabetes
Clinical Perspective
What Is New?
• Despite intensive risk factor management, cardiovascular disease remains a major cause of morbidity and mortality in diabetes mellitus, raising the question of whether diabetes prevention interventions may be important in reducing cardiovascular disease risk in diabetes mellitus.
• We found that men but not women with prediabetes treated with metformin for an average duration of 14 years in the Diabetes Prevention Program Outcome Study had lower coronary calcium scores than their placebo group counterparts.
• No difference in coronary calcium scores was observed in the group receiving a lifestyle intervention compared with the placebo group.
What Are the Clinical Implications?
• Several studies in subjects with diabetes mellitus have suggested that metformin treatment is associated with a reduction in cardiovascular disease events.
• These findings provide the first evidence that metformin may protect against coronary atherosclerosis in men with prediabetes, although demonstration that metformin reduces cardiovascular disease events in these subjects is needed before firm therapeutic implications of these findings can be determined.
• The reason for an absence of an effect in women is unclear; women have less coronary atherosclerosis and coronary calcium than men, and therefore, a metformin effect may be more difficult to identify in women.
Association criteria. 9 The diagnosis required confirmation by a second test, usually within 6 weeks. If diabetes mellitus was diagnosed and confirmed, diagnoses were reported to the participants, and their healthcare providers were informed. Study metformin or placebo was provided until hyperglycemia worsened to a fasting plasma glucose level ≥140 mg/ dL during DPP or an hemoglobin A 1c >7.0% during DPPOS. When this occurred, study drug was discontinued, and diabetes management was transferred to the participant's own healthcare provider. Although participants and their providers were informed of study-related blood pressure and lipid profile results, all medical management decisions were made by the participants' healthcare providers.
DPPOS Design
DPP showed that lifestyle intervention reduced incidence of diabetes mellitus by 58% and metformin by 31% compared with placebo during an average follow-up of 3.2 years. 4 At the end of DPP, the placebo and metformin groups were unmasked to their treatment assignment, and all participants were offered the lifestyle intervention in a group format during a 1-year bridge period. All surviving consented members (n=3149) of the 3 original DPP treatment arms, regardless of diabetes status, were invited to participate in the DPPOS, and 2776 participants (88%) joined. 10 Maintenance group lifestyle sessions, offered quarterly to all DPPOS participants, reinforced the basic lifestyle content and the weight loss and physical activity goals. In addition to the maintenance sessions, the original lifestyle group was offered supplementary group programs, reinforcing specific behavioral self-management activities, twice per year. During DPPOS, metformin, now unmasked, continued to be provided to participants randomized to metformin who remained eligible.
Clinical and Metabolic Variables
Standardized interviewer-administered questionnaires were used to obtain demographic and clinical data. Ever smoking was defined as prior use of ≥100 cigarettes. Blood pressure (BP), height, and weight were measured with standardized techniques. Hemoglobin A 1c , lipid profile, serum creatinine and urine albumin/creatinine ratio, and high-sensitivity C-reactive protein (CRP) and plasma tissue-type plasminogen activator (tPA) measurements were performed at the Central Biochemistry Laboratory (Northwest Lipid Research Laboratories, University of Washington, Seattle) as previously reported. 4, 6 Estimated glomerular filtration rate was calculated with the Chronic Kidney Disease Epidemiology Collaboration equation. 11 All assessments were performed at baseline and annually thereafter except for CRP and tPA, which were measured at baseline, at year 1 for DPP, and years 1 and 5 for DPPOS.
CAC Measurements
CAC was measured during year 10 of DPPOS in 2029 participants at all 25 sites according to previously published methods. 12 This represents 74% of the DPPOS cohort ( Figure 1 ). 
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Participants who weighed >350 lb at the time of scanning 6 were ineligible to participate in the CAC substudy because of the inability to acquire the relevant images on conventional equipment; 201 refused consent; 57 had a stent; 32 had atrial fibrillation; and 1 was pregnant. At the DPP baseline examination, participants who later underwent CAC studies had slightly higher minority race/ethnicity representation, were slightly younger, and had modestly lower BMI and lower systolic BP, and slightly fewer were smokers compared with those who did not undergo the procedure. Baseline metabolic measures were not different between the tested and untested groups except for slightly higher high-density lipoprotein cholesterol (HDL-C) levels in tested participants. The proportion with CAC measurements did not differ among treatment groups. Chest computed tomography was performed by certified technologists at each site using prospectively ECG-triggered scan acquisition at 50% of the R-R interval with a multidetector system, acquiring a block of four 2.5-mm slices for each cardiac cycle in a sequential or axial scan mode. Subjects were scanned twice, and the CAC measurement was calibrated against a phantom of known physical calcium concentration. A radiologist or cardiologist read all computed tomography scans at the central reading center (Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrence, CA) in a manner blinded to patient characteristics and treatment assignment. Discrepancies were reviewed, and agreement was obtained through consensus. For each scan, a total phantom-adjusted averaged Agatston score 13 was calculated, defined as the sum of calcium measures from the left main, left anterior descending, circumflex, and right coronary arteries.
Statistical Methods
The outcomes reported in these analyses are based on data obtained as of January 2, 2014, for the 2061 DPPOS participants who had CAC measurements. All treatment group comparisons were conducted on the basis of the original randomized interventions.
CAC was expressed both as a continuous variable (CAC severity) and as a categorical variable, mainly with a cut point of 0 (CAC presence) but also with cut points of10 and 100 Agatston units. CAC severity was considered the primary measure for this analysis because of greater power in analyzing continuous outcomes. CAC severity was analyzed by Tobit regression 14 of the CAC score with the lifereg procedure in SAS to account for the skewness resulting from the relatively large number of individuals with a CAC score of 0. CAC scores were transformed to log(CAC+1). The Tobit regression coefficient represents the log ratio of the geometric mean CAC score per unit increase in the covariate, assuming some true measurable calcification for all subjects, including those with undetectable levels. The adjusted CAC mean scores were expressed as the geometric mean by back-transforming the adjusted censored mean calculated from the Tobit model. The presence of CAC (CAC >0) was analyzed with logistic regression.
Prespecified analysis of treatment effect modification by demographic subgroups (baseline age, sex, and race) and diabetes status subgroups was conducted with the use of an interaction term in the models for CAC severity. If significant heterogeneity or interaction was detected among subgroups, then under the closure principle, 15 the difference between groups can be tested within each subgroup or category at the 0.05 level without the need to adjust for multiple tests. There was an interaction between sex and the metformin versus placebo effect on CAC presence (P=0.01) and CAC severity (P=0.08). Thus, all analyses were stratified by sex as a result of the interaction and of the expected differences between men and women. Other secondary analyses were not adjusted for multiple comparisons and are nominally significant at the 0.05 level.
RESULTS

Cohort Characteristics
Characteristics at baseline and follow-up of the cohort included in this analysis are shown in Table 1 . Mean age of participants at the time of scanning was 67±10 years in men and 63±9 years in women, with a mean study duration of 13.7±0.08 years since randomization. During DPPOS, 57% of nondiabetic metformin participants took ≥80% of the prescribed metformin dose and 70% took metformin in any amount compared with 1% of nondiabetic participants in the lifestyle and 3% in the placebo groups taking metformin prescribed outside the study. Mean years of metformin use in the metformin group was 9.6±4.6 years, whereas in the placebo and lifestyle groups, it was 1.7±2.9 and 1.3±2.5 years, respectively. Overall, diabetes mellitus developed in 59% of the placebo group compared with 54% and 51% in the metformin and lifestyle groups, respectively, at the time of scanning, with the mean duration of diabetes mellitus being 5.4±5.3, 4.5±5.1, and 3.8±4.6 years and mean hemoglobin A 1c being 6.0±0.7%, 5.9±0.6%, and 5.9±0.6% in the placebo, metformin, and lifestyle groups, respectively. The mean follow-up BMI was significantly lower in the metformin and lifestyle groups compared with the placebo group in both sexes, whereas systolic BP was lower in the lifestyle group in men only. Statin use increased significantly over time in DPPOS to >50% of participants, greater in men than in women; this was not different across treatment groups. The proportion of current smokers was low during the study, although a much higher proportion had a history of cigarette smoking. tPA levels were lower in the metformin and lifestyle groups compared with the placebo group in both sexes, whereas CRP was lower and HDL-C was higher in the active treatment groups among women only.
CAC Severity and Presence
The principal aim of this study was to evaluate treatment effects on the CAC score using our primary measure, CAC severity, derived from the logarithmically transformed CAC score ([log(CAC+1)]), as well as our Table 2 , CAC severity was significantly greater in men than in women (P<0.001). In men, CAC severity was significantly lower in the metformin than in the lifestyle group in unadjusted analyses and 41% lower in the metformin than placebo group after age adjustment. These effects persisted whether metformin group participants were defined as ever having used metformin or as currently using metformin (data not shown). No effect of metformin to lower CAC severity was seen in women. Similarly, among men but not in women, the presence of CAC >0 was significantly lower in the metformin group than in the other 2 groups (10.7% lower versus placebo and 11.7% lower versus lifestyle), but this was not the case for the CAC >10 or CAC >100 categories (Figure 2 ). There were no differences in CAC prevalence by categories among the 3 treatment groups. Differences in CAC severity but not CAC presence were observed between race/ethnic groups and by age categories, diabetes status, and statin use subgroups in both men and women (Table 2) . By age groups, both CAC severity and CAC >0 were significantly lower in the 25-to 44-year-old group among men in the metformin group versus the placebo group, with a tendency in this direction in the older age groups. CAC severity was significantly higher in the lifestyle than the placebo group among women in the 25-to 44-year-old group. CAC severity and presence among men in the metformin group tended to be lower in both those with and without diabetes mellitus and in all race/ethnic subgroups, although this did not reach significance (except for CAC >0 in those without diabetes mellitus). Among women, there was an interaction between diabetes status and treatment group for CAC severity (P=0.04). CAC severity was higher among statin users in both men and women.
Baseline age, systolic BP, estimated glomerular filtration rate (inversely), and non-HDL-C correlated with CAC severity in men and women and in all 3 treatment groups, as did mean systolic BP and estimated glomerular filtration rate during follow-up, but there was no relationship with hemoglobin A 1c levels and only weak associations with BMI, HDL-C, tPA, and CRP ( Figure 3A and 3B).
Models Adjusted for Demographic and CVD Risk Factors, Diabetes Status and Duration, and the Effects of Interventions on CAC Severity Stratified by Sex
To determine whether the lower CAC severity in men with metformin could be accounted for by demographic or cardiovascular risk factors or by diabetes development, their effects were examined in a series of multivariate models stratified by sex, comparing CAC severity in the metformin group with CAC severity in the placebo or lifestyle group (Figure 4) . After adjustment for age, the lower CAC severity in men in the metformin versus placebo group (Figure 4 , top left) was not attenuated by controlling for differences in race/ethnicity, baseline and follow-up risk factors, or diabetes status. Compared with men in the lifestyle group (Figure 4 , bottom left), CAC severity was also lower in the metformin group in the unadjusted model but with little change in the point estimate in all adjusted models. *Characteristics at baseline are expressed as mean±SD or percent as appropriate. No difference detected among treatment groups at baseline except for HDL-C in women (placebo=47.5, metformin=49.1, lifestyle=49.1) and smoking in women (placebo =8.0%, metformin=4.7%, lifestyle=4.5%).
†Characteristics during follow-up based on all annual visits before coronary artery calcium (CAC) measurement are expressed as mean (95% confidence interval) or median (IQR) over follow-up for continuous variables (as appropriate) and any report of medication over follow-up except for tPA and CRP that reflect data collected from Diabetes Prevention Program in year 1 and Diabetes Prevention Program Outcome Study in years 1 and 5. Ever smoked includes self-reported prior smoking of 100 cigarettes at baseline and during year of CAC measurement. Current smoker reflects baseline and at CAC measurement.
‡P<0.05 versus placebo. §P<0.05 versus metformin. ¶Diabetes mellitus duration calculated as years since diabetes mellitus diagnosis for participants with diabetes mellitus. Otherwise, duration is set at 0. 
DISCUSSION
We evaluated the effect of lifestyle intervention and metformin on CAC severity and presence in the longterm DPP/DPPOS. The major findings in this analysis are that in men but not in women, CAC severity and presence were lower in the metformin group compared with the placebo group, with a similar tendency in the metformin versus the lifestyle group. A tendency toward lower CAC in the men of the metformin group was also evident in race/ethnicity and age subgroups and was most prominent in younger men; these factors did not attenuate the effect of metformin in multivariate analysis. There were no CAC differences between the lifestyle and placebo groups. This study evaluated CAC cross-sectionally an average of 13 to 14 years after baseline randomization and suggests that compared with placebo, metformin treatment may have reduced early stages of plaque development in men. Notably, there was also a higher prevalence of CAC in this cohort than has been reported in other population studies such as the MultiEthnic Study of Subclinical Atherosclerosis. Possible explanations include the lower proportion of DPP subjects from minority race/ethnic groups (who have a lower prevalence of CAC compared with whites) and the higher prevalence of DPP participants with metabolic syndrome (which has been shown to be associated with higher CAC) than without this syndrome. 16, 17 Metformin has been demonstrated to reduce CHD events compared with diet 18 and sulfonylurea treatments 19 and compared with placebo in insulin-treated subjects with type 2 diabetes mellitus. 20 This is the first demonstration that metformin may have a beneficial effect on coronary atherosclerosis in a prediabetic population. Recently, a 1-year treatment program using metformin in subjects with HIV infection and metabolic syndrome demonstrated reduce CAC progression with metformin compared with placebo. 21 In contrast, metformin treatment had no effect on carotid intima-media thickness in the latter study or in a larger study of nondiabetic patients with CHD, 22 raising the possibility that coronary calcification may be a more sensitive marker of a metformin effect on atherosclerosis than is carotid intima-media thickness.
The mechanisms for protective effects of metformin on atherosclerotic vascular disease are not well understood. In addition to its antihyperglycemic action, metformin has been shown to improve endothelial function 23 and to favorably alter the lipid profile, 24 as well as lowering markers of inflammation and procoagulation. 6 Although we observed associations between CAC and baseline non-HDL-C, systolic BP, estimated glomerular filtration rate, CRP, tPA, and HDL-C, adjustment for cardiovascular risk factors did not account for the effect of metformin on CAC in men. Our present findings could reflect other effects of metformin on the pathogenesis of atherosclerosis, perhaps directly on the vessel wall. Recently, evidence for direct antiatherogenic actions of metformin involving adenosine monophosphate-activated protein kinase-mediated inhibition of monocyte-to-macrophage differentiation, 25 inhibition of vascular senescence, and downregulation of angiotensin II type 1 receptors has been demonstrated in experimental models. 26 In addition, metformin has been shown to inhibit vascular calcification in rat smooth muscle cells. 27 The sex difference in the effect of metformin on CAC that we observed has not been reported in studies of the preclinical or clinical effects of metformin on CVD. CAC severity was considerably lower in women than in men in our study, making it more difficult to identify an effect of metformin in women. On the other hand, more than half of the women had measurable CAC, yet there was no suggestion of an effect of metformin on CAC presence in women. At entry into the study, 36% of women were premenopausal. Atherogenesis proceeds more slowly in premenopausal women, especially in those who remain without diabetes mellitus, which might have contributed to the lack of effect of metformin in women. However, we were not able to detect an effect of metformin on the basis of a stratification of the female population into those ≥45 compared with <45 years of age at randomization (data not shown). Intriguingly, a similar sex dimorphism has previously been seen in DPP in terms of the prevention of metabolic syndrome 28 wherein metformin had a profound effect in men (P=0.002) yet no effect in women (P>0.20). This raises the possibility of hormonal interac- 
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tions; for example, it has been shown that metformin reduces testosterone levels in men 29 but not women. 30 It was notable that there was no reduction in the prevalence of clinically significant CAC, for example, CAC>100, among men in the metformin compared with the placebo group. That is, the effect of metformin on CAC was most evident in those with lower CAC scores. Although lower CAC scores are more susceptible to obesity-associated scanning artifacts, CAC scores at the lower end of the range are associated with a significant increase in the CHD event rate. 31 These findings could imply that the effect of metformin involves smaller and more recently calcifying plaques rather than well-established lesions. This is supported by the observation that the most prominent difference in CAC severity or presence was found in younger men, who would be expected to have atherosclerotic lesions earlier in their development than older men. Whether this means that metformin would have less clinical efficacy in older men must await testing of the effect of metformin on clinical outcomes.
It was also of interest to find that lower CAC in the metformin group was evident regardless of whether diabetes mellitus had developed. Although metformin has a durable effect to delay diabetes development and its use in prediabetes has been endorsed by the American Diabetes Association, 32 it is unknown whether the use of metformin before the development of diabetes mellitus has benefit for vascular complications. The present findings provide initial evidence that metformin may have a favorable effect on atherosclerosis both in the prediabetes phase and in the early period after the development of diabetes mellitus in men, suggesting that the effect of metformin on CAC in men does not depend on diabetes prevention. In this regard, it should be noted that the eligibility for DPP required both impaired glucose tolerance and a fasting glucose >95 mg/ dL, which would have excluded prediabetic subjects with milder degrees of dysglycemia. Therefore, these findings cannot be generalized to all subjects with prediabetes. Overall, 54% of the DPP/DPPOS cohort had developed diabetes mellitus at the time of scanning, but despite the presence of only modest hyperglycemia and a relatively short diabetes duration, we found that CAC severity was increased in those who developed diabetes mellitus compared with those who did not. Incident diabetes mellitus was identified in the DPP/DPPOS study by semiannual testing, which allows for a narrow definition of the timing of its biochemical onset and suggests that progression of dysglycemia to diabetes mellitus influences atherosclerosis. Taken together, these findings support the notion that the use of metformin within a few years before or after diabetes development has a beneficial effect on early stages of atherosclerosis in men.
The absence of an effect of lifestyle intervention on CAC in the face of the metformin finding is somewhat surprising because the lifestyle group experienced more significant reductions in the development of dyslipidemia, hypertension, and metabolic syndrome and a greater lowering of CRP levels than the metformin group. 6, 28, 33 Furthermore, lifestyle change had a greater long-term effect on diabetes prevention than metformin treatment during the first 10 years of follow-up. 33 Our findings extend those reported in a shorter 1-year Mediterranean diet intervention trial with a 3-year follow-up in a small study of subjects with CHD that found no effect on CAC progression. 34 Our findings are not concordant with the results of the Da Qing Diabetes Prevention Study, which found a significant reduction in mortality that was due largely to reduced CVD in the lifestyle intervention compared with the control group after 23 years of follow-up. However, this observation was seen in women but not men, and there were asymmetrical losses to follow-up and differences in age and smoking behavior between the 2 intervention groups. 35 It remains possible that there may be long-term effects on CVD outcomes with lifestyle intervention that are not reflected by its effect on CAC measured 10 to 13 years after randomization. One important difference between metformin and lifestyle in the DPP/DPPOS is the intensity of exposure over the period of observation. Metformin treatment was consistently used throughout the entire follow-up period, whereas the intensive period of lifestyle intervention averaged only 3.2 years, after which the net exposure was reduced, leading to reduced efficacy as measured by a diminution of weight loss.
Medication use might also have confounded these observations. During the post-DPP time period, lipidlowering therapy and antihypertensive therapy were increasingly prescribed in all treatment groups, and at the time of the CAC scan, lipid-lowering medications were used by 58% and antihypertensive medications by 67% of the entire cohort. These factors may have limited or obscured a beneficial effect of the lifestyle intervention on CAC. Indeed, as others have shown, we found that CAC severity (total plaque burden) was greater in statin users than nonusers in all treatment groups, and it has been suggested that statin use may be associated with plaque stabilization. 36 Nevertheless, CAC severity was lower in men in the metformin group despite the possible confounding effects of lipid-lowering and antihypertensive therapies and was in fact less prevalent in men taking statin medications in the metformin group. These observations suggest that metformin may slow or delay atherosclerosis independently of the effect of modern cardioprevention strategies in these subjects.
There are several limitations to this study. First, although metformin treatment was almost exclusive to the metformin intervention group, small numbers of participants from the other 2 intervention groups were taking out-of-study metformin. Second, the nature of the lifestyle intervention in the 3 treatment groups changed in the transition from DPP to DPPOS. Third, the study cohort was selected on the basis of glucose and body weight entry criteria, and those weighing >350 lb were excluded, so the results cannot be generalized to the entire prediabetic population. Finally, because CAC was measured only once at year 14, it was not possible to directly measure the effect of our interventions on CAC over time. Interpretation of the effect of the interventions was therefore based on the assumption that there were no differences in baseline CAC given the randomization of subjects into intervention groups at baseline. We found no differences in cardiometabolic risk factors at baseline between treatment groups except for slightly lower HDL-C and higher smoking rates in women in the placebo group only.
CONCLUSIONS
These findings add support to the evidence base that metformin may protect against atherosclerotic vascular disease early in diabetes development and potentially extend the range of this action to include high-risk male prediabetic subjects. Whether these findings translate into beneficial effects on CVD events will require ongoing follow-up. 
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